In fact, alterations in KRAS have been identified in 25% of all cancers, where some cancers like pancreatic cancer contain extremely high mutation rates (90%), while others, such as prostate cancer, show lower mutation rates (7%) [1,3]. This evidence concerns the gene KRAS and Familial prostate cancer.